MPT WWW
Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.

Commentary

California's Real Drug Problem
Investor's Business Daily, 8-24-06

Investor's Business Daily weighs in with a scathing editorial on California’s embrace of price controls for prescription drugs.

It sounds good on paper and may be an easy sell politically, but it's sure to fail. Under the deal, more than 5 million Californians, nearly 15% of the state's population, will benefit from rigged discounts on prescription medicines.

Most of the cut–rate drugs will go to families of four or more who earn up to about $60,000 a year, or three times the federally established poverty level. Another 400,000 who have high medical bills relative to their incomes yet earn a bit beyond that threshold will also be eligible.

The discounts, which the drug industry has three years to negotiate with the state, will cut as much as 40% off brand-name medications and up to 60% off generics.

Companies that don't participate will be penalized by having their medications taken off the list of approved drugs paid for by Medi–Cal, the state's health insurance program for the poor that is a multibillion–dollar market for drug companies.

"This is a huge victory for the needy," said Assembly Speaker Fabian Nunez, a Los Angeles Democrat. "This goes a long way toward correcting the wrong that was done at the ballot box in November." Oh, yes, the "wrong" done at the ballot box.

Last November, voters overwhelmingly rejected two initiatives aimed at providing discount drugs to Californians. Proposition 78 was opposed by 58.5% of the voters, Proposition 79 by 60.7%.

So much for the will of the people. Californians should just all turn their lives over to Nunez and the enlightened in Sacramento.

And the needy? It's too much to ask bureaucrats to decide who is needy. A measure of income divided by family size is not sufficient. Too many factors—from spending habits to work history to issues of personal responsibility—must be weighed to determine who is truly needy. The government is not up to that task.

The real needy are those—rich, poor and in between—who won't be able to get the medications they need in California because drug makers pulled out of the state rather than sell their products at costs that will hurt their businesses.

The needy are those who will lose their jobs when the drug companies pull out of the state, which is rich in biotech firms, as they inevitably will. The needy are Americans everywhere who would have benefited in the future from the R&D that drug companies had to curtail because their profits fell in the largest state in the country. All this thanks to discounts coerced by legislative action against the people's will.



Project FDA.
  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org